Related Experiment Video
Updated: Apr 7, 2026

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
Published on: July 3, 2014
Propranolol Reduces Cancer Risk: A Population-Based Cohort Study
Ping-Ying Chang1, Wen-Yen Huang, Cheng-Li Lin
1From the Division of Hematology/Oncology, Department of Internal Medicine (P-YC, T-CH, Y-YWu, J-HC); Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center (W-YH); Institute of Clinical Medicine, National Yang-Ming University, Taipei (W-YH); Management Office for Health Data, China Medical University Hospital (C-LL); College of Medicine (C-LL); Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University (C-HK); and Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan (C-HK).
Propranolol, a beta-blocker, was associated with a reduced risk of developing several cancers, including head and neck, esophagus, stomach, colon, and prostate cancers. This finding suggests a potential protective role for propranolol in cancer prevention.
Area of Science:
- Oncology
- Pharmacology
- Epidemiology
Background:
- Beta-blockers (β-blockers) show potential anticancer effects in preclinical models.
- Clinical evidence on β-blockers' impact on cancer risk and outcomes remains inconsistent.
Purpose of the Study:
- To investigate the association between propranolol use and the risk of developing cancer.
- To evaluate the potential anticancer effects of propranolol in a large patient cohort.
Main Methods:
- A retrospective cohort study using Taiwan's National Health Insurance Research Database (2000-2011).
- Propensity score matching was used to create comparable propranolol and non-propranolol user cohorts.
- Cox proportional hazard models analyzed cancer risk (Hazard Ratio, HR) associated with propranolol treatment.
Main Results:
- Propranolol use was linked to a significantly lower overall cancer incidence (HR: 0.75; 95% CI: 0.67-0.85).
- Reduced risks were observed for head and neck (HR: 0.58), esophagus (HR: 0.35), stomach (HR: 0.54), colon (HR: 0.68), and prostate cancers (HR: 0.52).
- The protective effect was most pronounced with propranolol exposure exceeding 1000 days for specific cancer types.
Conclusions:
- Propranolol treatment is associated with a reduced risk of developing head and neck, esophagus, stomach, colon, and prostate cancers.
- The findings support a potential chemopreventive role for propranolol.
- Further prospective studies are warranted to confirm these observations.
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Antihypertensive Drugs: Types of β-Blockers
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Coronary Artery Disease IV: Preventive Measures

